PLAINSBORO, N.J., Oct. 3, 2011 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the launch of the IntegraTM CUSA NXT™ Extended Length Tip for Integra’s CUSA NXT™ and CUSA Selector® Ultrasonic Tissue Ablation Systems. The IntegraTM CUSA NXT™ Extended Length Tip has received 510(k) clearance from the United States Food and Drug Administration (FDA). Integra will feature the Integra™ CUSA NXT™ Extended Length Tip at the 2011 Congress of Neurological Surgeons (CNS) annual meeting, October 1-6, 2011, in Washington, DC.
The CUSA® systems are well recognized medical devices used in neurosurgical and other surgical procedures for the controlled and selective removal of soft tissues that are near critical structures. The CUSA® systems may also be used for delicate bone sculpting procedures.
The new Integra ™ CUSA NXT™ Extended Length Tip expands the surgical applications for the CUSA NXT™ and CUSA Selector® Ultrasonic Tissue Ablation systems. Driven by the CUSA Selector® 35 kHz handpiece, the Integra ™ CUSA NXT™ Extended Length Tip allows surgeons to use ultrasonic tissue ablation in procedures characterized by a long path to the target tissue. The high frequency handpiece enables a superficial, controlled tissue effect, often desired in neurosurgery when working around critical structures.
The 35 kHz Extended Length Tip features a one-piece tip design, low profile silicone flue, and an ergonomic shroud, all single-use items packaged in a procedure pack. This simplifies handpiece set-up prior to the procedure and helps save valuable time in the operating room.
“We are excited to expand the tip selection for Integra’s CUSA NXT™ and CUSA Selector® platforms,” said Peter Colgan, Director, Tissue Ablation Marketing. “We can now help neurosurgeons limit uncertainty in surgical procedures where the surgical approach to the target tissue calls for a longer length tip.”
Over 2,000 centers worldwide rely on CUSA® ultrasonic surgical ablation technology for a variety of procedures, including the removal of soft tissues associated with brain and abdominal tumors. Integra currently offers a diverse line of CUSA® tissue ablation products, including the CUSA NXT™, CUSA EXcel®+, CUSA EXcel®, CUSA Selector®, and CUSA® DissectronTM systems.
Integra is a leading provider of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neuro-trauma, and related critical care.
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading “Risk Factors” included in Item IA of Integra’s Annual Report on Form 10-K for the year ended December 31, 2010 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation